Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
Clinical trial NCT06540508 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06540508
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- ENROLLING_BY_INVITATION
- Study type
- OBSERVATIONAL
- Start date
- 2023-02-01
- Primary completion
- 2025-02-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.